DrugPatentWatch Database Preview
Emd Serono Company Profile
» See Plans and Pricing
What is the competitive landscape for EMD SERONO, and when can generic versions of EMD SERONO drugs launch?
EMD SERONO has nine approved drugs.
There are twelve US patents protecting EMD SERONO drugs.
There are one hundred and seventy-one patent family members on EMD SERONO drugs in forty countries and seventy supplementary protection certificates in sixteen countries.
Summary for Emd Serono
| International Patents: | 171 |
| US Patents: | 12 |
| Tradenames: | 8 |
| Ingredients: | 7 |
| NDAs: | 9 |
Drugs and US Patents for Emd Serono
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emd Serono Inc | TEPMETKO | tepotinib hydrochloride | TABLET;ORAL | 214096-001 | Feb 3, 2021 | RX | Yes | Yes | Get Started for $10 | Get Started for $10 | |||||
| Emd Serono | NOVANTRONE | mitoxantrone hydrochloride | INJECTABLE;INJECTION | 019297-002 | Dec 23, 1987 | DISCN | Yes | No | Get Started for $10 | Get Started for $10 | |||||
| Emd Serono Inc | CETROTIDE | cetrorelix | INJECTABLE;INJECTION | 021197-002 | Aug 11, 2000 | DISCN | No | No | Get Started for $10 | Get Started for $10 | |||||
| Emd Serono Inc | TEPMETKO | tepotinib hydrochloride | TABLET;ORAL | 214096-001 | Feb 3, 2021 | RX | Yes | Yes | 9,284,300 | Get Started for $10 | Y | Get Started for $10 | |||
| Emd Serono | NOVANTRONE | mitoxantrone hydrochloride | INJECTABLE;INJECTION | 019297-001 | Dec 23, 1987 | DISCN | Yes | No | Get Started for $10 | Get Started for $10 | |||||
| Emd Serono Inc | TEPMETKO | tepotinib hydrochloride | TABLET;ORAL | 214096-001 | Feb 3, 2021 | RX | Yes | Yes | 8,580,781 | Get Started for $10 | Y | Y | Get Started for $10 | ||
| Emd Serono Inc | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 020443-001 | Sep 26, 1997 | DISCN | Yes | No | Get Started for $10 | Get Started for $10 | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Emd Serono
International Patents for Emd Serono Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2349136 | Get Started for $10 |
| Canada | 2692867 | Get Started for $10 |
| Japan | 2018165271 | Get Started for $10 |
| Spain | 2382554 | Get Started for $10 |
| Hong Kong | 1150266 | Get Started for $10 |
| Poland | 1608344 | Get Started for $10 |
| Eurasian Patent Organization | 200600403 | Get Started for $10 |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Emd Serono Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1827461 | 18C1008 | France | Get Started for $10 | PRODUCT NAME: CLADRIBINE; REGISTRATION NO/DATE: EU/1/17/1212 20170824 |
| 1506211 | 300677 | Netherlands | Get Started for $10 | PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121 |
| 1827461 | 1890010-0 | Sweden | Get Started for $10 | PRODUCT NAME: CLADRIBINE; REG. NO/DATE: EU/1/17/1212 20170824 |
| 0299402 | 099C0031 | Belgium | Get Started for $10 | PRODUCT NAME: ACETATE DE CETRORELIX; REGISTRATION NO/DATE: EU/1/99/100/001 19990413 |
| 1827461 | C01827461/01 | Switzerland | Get Started for $10 | PRODUCT NAME: CLADRIBIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66831 19.03.2019 |
| 1506211 | 42/2014 | Austria | Get Started for $10 | PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES DAVON UND METFORMIN UND EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES DAVON; REGISTRATION NO/DATE: EU/1/13/900 (MITTEILUNG) 20140121 |
| 1412357 | 122008000046 | Germany | Get Started for $10 | PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE SITAGLIPTINPHOSPHAT- MONOHYDRAT, IN KOMBINATION MIT METFORMIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716 FIRST REGISTRATION: CH/LI 58450 01 58450 02 58450 03 20080408 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
